I
IMRX
Immuneering Corp
5.00
-0.25-4.76%After Hours: 5.09 +0.09 +1.88%19:54 02/20 EST
OPEN/PREV CLOSE5.25/5.25
TODAY RANGE4.930-5.29
VOL689.71K
MARKET CAP322.85M
52 WEEK RANGE1.100-10.08
AVG VOL (3M)1.72M
% TURNOVER1.07%
TURNOVER--
P/E (TTM)-2.8043
% RANGE6.81%
EPS(TTM)-1.7830
P/E(FORWARD)-3.5461
P/B1.392
BVPS3.591
DIVIDEND--
P/S4,050.00
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP264.94M
SHARES OUTSTANDING64.57M
NEXT EARNINGS--
FREE FLOAT52.99M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
TipRanks·01/22 02:02
Top Immuneering Insider Quietly Ramps Up Stake in Bold New Buy
TipRanks·01/21 02:01
Insider Makes Bold Move With Fresh Buy Into Biotech Player
Reuters·01/20 14:18
Immuneering Director Thomas J. Schall Reports Acquisition of Common Shares
TipRanks·01/17 02:01
Top Immuneering Insider Quietly Boosts Stake in Bold New Move
TipRanks·01/16 02:03
Top Immuneering Executive Makes Bold Move With Fresh Stock Purchase
NASDAQ·01/15 18:58
Thursday 1/15 Insider Buying Report: IMRX, DLPN
Reuters·01/15 13:06
Immuneering Chief People Officer Leah R. Neufeld Acquires Common Shares
TipRanks·01/15 02:02
Immuneering Insider Makes Bold New Bet on Company’s Future
Benzinga·01/14 15:00
Looking Into Immuneering Corp's Recent Short Interest
Benzinga·01/10 13:31
Benzinga Bulls And Bears: Chevron, Palantir, Aquestive — And Real Estate Stocks Plummet
Seeking Alpha·01/08 22:45
Immuneering: Strong Buy Despite Decline In Share Price On Atebimetinib Data
Dow Jones·01/08 20:17
Immuneering Falls on Survival Data in Pancreatic-Cancer Study
Same Industry
Name/Symbol
Change%
Price